Eli Lilly's Retatrutide kan miljarden waard zijn

Eli Lilly domineert de markt voor gewichtsverlies met Retatrutide, dat mogelijk miljarden dollar…

https://yieldgraph.nl/blog/eli-lillys-retatrutide-kan-miljarden-waard-zijn/ #investeren #beleggen #aandelen #beursnieuws #lly #WallStreet #YieldGraph

#LLY $LLY

Buyer zone formed. Local minimum confirmed.

https://tr3n.do/stocks/lly?utm_source=bluesky

$VKTX surged 25% as new obesity drug data increases competitive pressure on $NVO and $LLY.

The obesity drug market is getting crowded fast. 👀

#VKTX #NVO #LLY #Biotech #Stocks #Trading

There are a lot of ways to get exposure across that stack, from biological data and diagnostics through #TEM, to synthetic DNA through #TWST, AI drug discovery through #RXRX, and scaled drug developers like #LLY that have the capital and infrastructure to commercialize what actually works.

Lilly's head‑to‑head weight‑loss data (20.2% vs 13.7%) shows genuine clinical leadership—the active pharmaceutical ingredient of its competitive edge. #LLY https://post.kapualabs.com/yu55ra28

Eli Lilly's incretin franchise hinges on tirzepatide—about 65% of Q2 revenue comes from just Mounjaro & Zepbound. That concentration creates a formulation risk worth watching. #LLY https://post.kapualabs.com/2p8upujr

Lilly’s Q2 revenue jumped 48% YoY, driven by Mounjaro & Zepbound – see why concentration matters for its future https://post.kapualabs.com/43vwt42m #LLY

Eli Lilly's Q2 revenue beat contrasts with a low‑to‑mid‑teens price drag and 65% reliance on Mounjaro/Zepbound – a contrarian risk take. Details: https://post.kapualabs.com/mv7b5wud #LLY

Eli Lilly’s Q2 2026 revenue hit $22.97B, up 48% YoY and beating the $20.82B estimate. https://post.kapualabs.com/3auf3sfh #LLY

Eli Lilly (LLY) shows no verifiable price, volume or momentum data through Sep 2026 — technical blank means no trend signal. Wait for tape confirmation before acting. https://post.kapualabs.com/2p7fjyhr #LLY

Eli Lilly’s Q2 2026 revenue of $22.97B topped estimates by $2.15B, driven by Mounjaro/Zepbound volume. See the yield‑shield analysis: https://post.kapualabs.com/mwx6j5wr #LLY

Eli Lilly’s Q2 2026 revenue jumped 48% YoY to $22.97B, beating the $20.82B estimate and highlighting its GLP-1 S‑curve edge. https://post.kapualabs.com/3xpndvn9 #LLY

Eli Lilly Q2 2026 revenue up 48% YoY to $22.97B, beating estimates. #LLY https://post.kapualabs.com/z6zk3wjf

Explore why Eli Lilly’s ~65% H1 revenue from tirzepatide (Mounjaro/Zepbound) is the core risk driver shaping its growth outlook #LLY https://post.kapualabs.com/2p86w5y2

LLY technical review finds no price, volume, or options data, so no trend, liquidity, or risk signals can be grounded. The tape offers no verdict—wait for confirmed data before acting. https://post.kapualabs.com/2x6bf9zx #LLY

567 claims across 5,440 sources to Sep 2026 yield one measured result for #LLY: absence of usable macro evidence — no rates, FX, or inflation inputs. Why withholding estimates is the disciplined inference: https://post.kapualabs.com/2as9e45s

Eli Lilly klopt triljoendollargrens; groei buiten VS sleutel

Eli Lilly noteert dicht bij $1.150 na een stijging van 52% in een jaar e…

https://yieldgraph.nl/blog/eli-lilly-klopt-triljoendollargrens-groei-buiten-vs-sleutel/ #investeren #beleggen #aandelen #beursnieuws #lly #WallStreet #YieldGraph

History rhymes: for LLY, the crowd leaves no footprints—no analyst ratings, institutional holdings, or insider trades to read. Sentiment has no anchor. https://post.kapualabs.com/62duswph #LLY

Eli Lilly's Q2 2026 revenue jumped 48% YoY to $22.97B, beating estimates, powered by Mounjaro & Zepbound volume growth. See the full breakdown: https://post.kapualabs.com/35evxhzd #LLY

Discover how Eli Lilly's Q2 revenue surged 48% YoY, with Mounjaro & Zepbound delivering ~65% of sales. Dive into the fundamentals. #LLY https://post.kapualabs.com/49zmvp6k